---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-072825"
form_type: "8-K"
ticker: "HCWB"
cik: "0001828673"
company_name: "HCW Biologics Inc."
filed_at: "2025-05-15T23:59:59+00:00"
generated_at: "2026-05-21T05:34:49.303836+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.82
calibrated_materiality_score: 0.82
confidence: "high"
source: SEC EDGAR
---

# HCW Biologics Q1 net loss $2.2M; closed $5M equity offering; going concern doubt

## Summary
- Q1 revenue $5,065 vs $1.1M prior year; net loss $2.2M vs $7.5M prior; R&D down 30% to $1.5M; G&A up 42% to $2.2M.
- Closed $5.0M equity offering on May 15 with one institutional investor; used to fund Phase 1 trial for HCW9302 in alopecia areata.
- Delivered technology report to WY Biotech for licensing of HCW11-006; expects $7.0M upfront fee after 30-day diligence.
- Received Nasdaq compliance letter for bid price, public float, MVPHS; must comply with all listing rules by June 16, 2025.
- Substantial doubt about ability to continue as going concern for 12 months; additional funding needed.

## SEC filing metadata
- accession: 0000950170-25-072825
- form_type: 8-K
- ticker: HCWB
- cik: 0001828673
- company_name: HCW Biologics Inc.
- filed_at: 2025-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.82
- calibrated_materiality_score: 0.82
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1828673/000095017025072825/0000950170-25-072825-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1828673/000095017025072825/hcwb-20250515.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-072825
- JSON: https://secwatch.observer/filing/0000950170-25-072825.json
- Plain text: https://secwatch.observer/filing/0000950170-25-072825.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.